Answers are grounded in this paper and cite their sources.
Clinical trial reveals pandemic-related visit restrictions altered screening outcomes for undiagnosed chronic obstructive pulmonary disease in primary care, indicating potential selection bias.
To the Editor:The impact of the coronavirus disease (COVID-19) pandemic on healthcare systems and clinical trial implementation has been widely reported (1-8), although little has been published with regard to study outcomes.Primary care-based respiratory-related clinical studies experienced pandemic challenges related to in-person study enrollment and visits and potential aerosol-generating testing such as spirometry (9-11).When resumed, such studies had to restrict enrollment to those patients who were allowed to attend in-person office visits, which often excluded anyone with respiratory symptoms (12).This letter compares the prepandemic (pre period) and poststudy resumption (post period) primary outcomes from the COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) study to identify undiagnosed clinically significant chronic obstructive pulmonary disease (COPD) in primary care (13,14).Specifically, the CAPTURE screening tool five-question and peak flow responses and participant characteristics were compared for the two periods.The prepandemic enrollment period was October 12, 2018, through March 17, 2020, and the postpandemic enrollment was August 13, 2020, through April 1, 2022.The analyses focused on the primary outcome, the operating characteristics of the CAPTURE tool for identifying clinically significant COPD, which was defined as COPD with postbronchodilator spirometry results of FEV 1 /FVC ,0.70 (or ,0.65 if no postbronchodilator spirometry was available) plus an FEV 1 ,60% predicted or one or more exacerbation-like respiratory events in the prior 12 months.To facilitate understanding of outcome changes, we compared the participants' CAPTURE tool responses, their demographics, health history, and COPD status during the two periods.Adults aged 45-80 years without prior COPD diagnoses were enrolled from among people visiting one of 100 primary care member practices of seven practice-based research groups from rural New York and Colorado, rural and urban North Carolina and Oregon, and inner-city Los Angeles and Chicago.Pandemic-related changes to the study included negative verbal screening for potential COVID-19, with practices not allowing in-person visits required for enrollment if patients reported any acute respiratory symptoms.Enrolled and consenting participants provided demographics; a self-reported medical history; results from the COPD Assessment Test (CAT), a patient-reported outcome of health status (15); modified Medical Research Council dyspnea index results (16); their history of respiratory illnesses in the prior 12 months (17); and their smoking status and tobacco exposure (18).
No takes yet. Share an insight, caveat, or question.
Yawn et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: